TERNS PHARMACEUTICALS INC. - COMMON STOCK

Terns Pharmaceuticals to Participate in Upcoming November Investor Conferences

09 Nov 2023 08:05:00 By Nasdaq GlobeNewswire

Terns Pharmaceuticals Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(C)(4)

03 Nov 2023 16:05:00 By Nasdaq GlobeNewswire

Terns Pharmaceuticals Announces First Participant Dosed in Phase 1 Clinical Trial of TERN-601 Oral GLP-1 Receptor Agonist for Treatment of Obesity

02 Nov 2023 16:05:00 By Nasdaq GlobeNewswire

Terns Pharmaceuticals to Participate in Upcoming Investor Conferences

19 Oct 2023 16:05:00 By Nasdaq GlobeNewswire

Terns Pharmaceuticals Announces Global Phase 1 Clinical Trial Design of TERN-701 for the Treatment of Chronic Myeloid Leukemia

16 Oct 2023 08:05:00 By Nasdaq GlobeNewswire

Terns Pharmaceuticals Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(C)(4)

03 Oct 2023 16:05:00 By Nasdaq GlobeNewswire

Terns Pharmaceuticals Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(C)(4)

06 Sep 2023 16:05:00 By Nasdaq GlobeNewswire

Terns Pharmaceuticals to Participate in Upcoming September Investor Conferences

05 Sep 2023 16:05:00 By Nasdaq GlobeNewswire

Terns Pharmaceuticals Reports Second Quarter 2023 Financial Results and Corporate Updates

08 Aug 2023 16:15:00 By Nasdaq GlobeNewswire

Terns Achieves Primary Endpoint and All Secondary Endpoints in Phase 2a DUET Trial of THR-β Agonist TERN-501 in NASH

08 Aug 2023 16:05:02 By Nasdaq GlobeNewswire

Terns Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(C)(4)

03 Aug 2023 18:00:00 By Nasdaq GlobeNewswire

Terns Pharmaceuticals Announces Leadership Transition

03 Aug 2023 17:05:00 By Nasdaq GlobeNewswire

Terns Pharmaceuticals to Host Virtual Key Opinion Leader Event to Discuss TERN-701 and Advances in the Treatment Landscape for Chronic Myeloid Leukemia

18 Jul 2023 16:05:00 By Nasdaq GlobeNewswire

Terns Pharmaceuticals Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(C)(4)

05 Jul 2023 16:05:00 By Nasdaq GlobeNewswire

Terns Pharmaceuticals Highlights New Preclinical Data for TERN-601 Program in Obesity at the ADA’s 83rd Annual Scientific Session and Upcoming Events

26 Jun 2023 16:05:00 By Nasdaq GlobeNewswire

Terns Pharmaceuticals to Present at Goldman Sachs 44th Annual Global Healthcare Conference

06 Jun 2023 16:30:00 By Nasdaq GlobeNewswire

Terns Pharmaceuticals Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(C)(4)

02 Jun 2023 16:05:00 By Nasdaq GlobeNewswire

Terns Pharmaceuticals Announces Publication of TERN-701 Trial-in-Progress Abstract for the 2023 ASCO Annual Meeting

25 May 2023 17:05:00 By Nasdaq GlobeNewswire

Terns Pharmaceuticals to Present at Upcoming Investor Conferences

24 May 2023 16:05:00 By Nasdaq GlobeNewswire

Terns Pharmaceuticals to Highlight New Preclinical Data for TERN-601 Program in Obesity at the American Diabetes Association’s 83rd Annual Scientific Sessions

22 May 2023 16:05:00 By Nasdaq GlobeNewswire